Shots: The integration of innovative technologies in healthcare, such as digital health platforms and AI-enabled applications, is transforming the way diseases are detected, diagnosed, treated, and prevented The global Digital Health market is expected to reach $197.88B in 2025 and grow at a CAGR of 6.88%, reaching $258.25B by 2029 PharmaShots presents a concise report…
The field of orthodontics is undergoing a significant transformation, driven by cutting-edge technologies and patient-centric approaches. Innovations in this area are not only enhancing treatment outcomes but also revolutionizing the overall patient experience. As these advancements continue to evolve, they are shaping the future landscape of orthodontic care.The evolving landscape of orthodontic care is…
The ISPE Singapore Affiliate Conference & Exhibition is one of the largest and most renowned pharmaceutical manufacturing shows in Singapore for pharmaceutical and biomanufacturing professionals. The annual event highlights the best practices and services from manufacturing facility design to finished products.Click here to register now!We are thrilled to announce that we are taking the…
PharmaShots conducted its fourth “Spotlight- Company of the Month with TAE Life Sciences”. In conversation with Bruce Bauer (CEO) & Kendall Morrison (CSO) at TAE Life Sciences, they both shared insights on TAE Life Sciences' vision, upcoming plans, technologies used, and developing products. Bruce and Kendall spoke about TAE’s novel treatment options which could potentially…
Shots:Michael spoke about the addition of new biopharma products through QIAcuity series of digital PCR (dPCR) instruments to its digital PCR portfolioHe also talked about how QIAGEN’s dPCR assays are quicker than systems as it was launched in four different master mixes allowing experiments leading to precise resultsThe interview gives an understanding of…
Authored by Frank Nestle, Global Head of Research and Chief Scientific Officer, SanofiOver the past few decades, progress in understanding the molecular drivers of disease has revealed exciting new opportunities for targeting common and complex conditions in the fields of Immunology, Oncology, Neurology, and Rare Diseases. At Sanofi, we are going beyond incremental therapeutic…

